Spark submission brings first gene therapy for genetic disease closer – The Pharma Letter (registration)
|
Spark submission brings first gene therapy for genetic disease closer
The Pharma Letter (registration) US biotech firm Spark Therapeutics (Nasdaq: ONCE) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Luxturna, the proposed trade name for voretigene neparvovec, an investigational, one-time gene … |
